Crinetics Pharmaceuticals (CRNX) Expected to Announce Earnings on Thursday

Crinetics Pharmaceuticals (NASDAQ:CRNX) is anticipated to announce its Q4 2025 results after the market closes on Thursday, February 26th. Analysts expect Crinetics Pharmaceuticals to post earnings of ($1.35) per share and revenue of $4.3230 million for the quarter. Individuals may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, February 26, 2026 at 4:30 PM ET.

Crinetics Pharmaceuticals Stock Performance

Shares of NASDAQ CRNX opened at $43.79 on Tuesday. The firm has a 50 day moving average price of $49.16 and a two-hundred day moving average price of $42.88. The stock has a market cap of $4.47 billion, a P/E ratio of -9.67 and a beta of 0.19. Crinetics Pharmaceuticals has a 52-week low of $24.10 and a 52-week high of $57.99.

Analyst Ratings Changes

A number of analysts recently weighed in on CRNX shares. Citizens Jmp decreased their price objective on Crinetics Pharmaceuticals from $108.00 to $105.00 and set a “market outperform” rating for the company in a report on Thursday, January 8th. Morgan Stanley raised their price target on shares of Crinetics Pharmaceuticals from $77.00 to $80.00 and gave the stock an “overweight” rating in a report on Tuesday, January 6th. Wall Street Zen downgraded shares of Crinetics Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, February 14th. Lifesci Capital raised Crinetics Pharmaceuticals to a “strong-buy” rating in a report on Friday, February 13th. Finally, The Goldman Sachs Group upgraded shares of Crinetics Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $67.00 target price for the company in a research note on Monday, January 12th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $75.78.

Insider Transactions at Crinetics Pharmaceuticals

In other news, insider Isabel Kalofonos sold 2,500 shares of the firm’s stock in a transaction on Monday, January 5th. The stock was sold at an average price of $55.00, for a total transaction of $137,500.00. Following the completion of the sale, the insider directly owned 834 shares of the company’s stock, valued at $45,870. This trade represents a 74.99% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 6.00% of the stock is owned by company insiders.

Institutional Trading of Crinetics Pharmaceuticals

Large investors have recently added to or reduced their stakes in the stock. Brooklyn Investment Group grew its stake in shares of Crinetics Pharmaceuticals by 14,878.4% during the 3rd quarter. Brooklyn Investment Group now owns 5,542 shares of the company’s stock worth $231,000 after acquiring an additional 5,505 shares during the period. Walleye Capital LLC bought a new stake in Crinetics Pharmaceuticals in the 4th quarter valued at about $230,000. Cetera Investment Advisers purchased a new stake in Crinetics Pharmaceuticals during the fourth quarter valued at about $224,000. Meeder Advisory Services Inc. bought a new position in Crinetics Pharmaceuticals during the fourth quarter worth about $216,000. Finally, Dark Forest Capital Management LP purchased a new position in shares of Crinetics Pharmaceuticals in the third quarter worth about $213,000. Hedge funds and other institutional investors own 98.51% of the company’s stock.

Crinetics Pharmaceuticals Company Profile

Crinetics Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases. The company’s proprietary platform leverages insights into hormone receptor signaling to design small-molecule candidates that address conditions driven by dysregulated hormone activity. Crinetics’ research efforts center on targeting somatostatin, vasopressin and other GPCR-mediated pathways with orally bioavailable molecules intended to improve patient convenience and adherence.

The company’s lead product candidate, paltusotine (formerly CRN04777), is a selective, non-peptide somatostatin receptor type 2 agonist being evaluated for the treatment of acromegaly and carcinoid syndrome diarrhea.